睿知中国医院研究地图
候选清单

杭州

杭州市第一人民医院

Hangzhou First People's Hospital

在本站收录的 61 种疾病中,这家医院列在其中 22 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

杭州市第一人民医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma8 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma67 篇牵头论文
  3. 胃癌Stomach cancer11 篇牵头论文
  4. 肺癌Lung cancer51 篇牵头论文
  5. 胰腺癌Pancreatic cancer23 篇牵头论文牵头 1 项开放试验
  6. 乳腺癌Breast cancer21 篇牵头论文
  7. 胶质瘤Glioma8 篇牵头论文
  8. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  9. 骨肉瘤Osteosarcoma3 篇牵头论文
  10. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma5 篇牵头论文
  12. 淋巴瘤Lymphoma7 篇牵头论文
  13. 冠心病Coronary heart disease16 篇牵头论文
  14. 先天性心脏病Congenital heart disease1 篇牵头论文
  15. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  16. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
  17. 法布雷病Fabry disease1 篇牵头论文
  18. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  19. 白塞病Behçet disease1 篇牵头论文
  20. IgA 肾病IgA nephropathy0 篇牵头论文
  21. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  22. Leber 遗传性视神经病变Leber hereditary optic neuropathy0 篇牵头论文

未列出的收录疾病:食管鳞状细胞癌、肝母细胞瘤、脊索瘤、神经母细胞瘤、尤文肉瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 3320232024: 2220242025: 222025

杭州有 8 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题影像与人工智能放疗技术副作用与生活质量
论文中的科室耳鼻喉/头颈外科影像/核医学科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 67 篇,占 0.4%。

牵头论文
67
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 131320212022: 191920222023: 151520232024: 8820242025: 11112025

杭州有 7 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现手术与肝移植
论文中的科室普外/肝胆胰外科影像/核医学科肿瘤内科临床试验/研究机构
牵头的论文67
  1. Disphosphate based hydrogel microspheres for targeted transarterial radioembolization and chemoembolization therapies.2026Journal of advanced research免费全文
  2. Mitochondria-Targeted Icaritin Nanoparticles Induce Immunogenic Cell Death in Hepatocellular Carcinoma.2025ACS applied materials & interfaces
  3. Hepatic Arterial Infusion Chemotherapy Enhances the Efficacy of Lenvatinib Plus PD-1 Inhibitors in Hepatocellular Carcinoma Patients with Tumor Thrombosis in the Inferior Vena Cava and/or Right Atrium.2025Academic radiology
  4. A Novel tRF, HCETSR, Derived From tRNA-Glu/TTC, Inhibits HCC Malignancy by Regulating the SPBTN1-catenin Complex Axis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. Deciphering the Role of Necroptosis-Related Long Non-coding RNAs in Hepatocellular Carcinoma: A Necroptosis-Related lncRNA-Based Signature to Predict the Prognosis of Hepatocellular Carcinoma.2025Applied biochemistry and biotechnology
  6. Long non-coding RNA in hepatocellular carcinoma: mechanistic insights and therapeutic perspectives.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  7. HCC-derived CX3CL1 affects hepatocellular carcinoma prognosis and CX3CR1 + MDSC infiltration.2025European journal of medical research免费全文
  8. METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.2025Future oncology (London, England)免费全文
  9. Impact of Donor CMV-Seropostive Grafts on Prognosis of Liver Transplantation for Hepatocellular Carcinoma.2025Journal of medical virology
  10. Multi-omic analysis reveals elevated BRI3BP expression associated with hepatocellular carcinoma progression and poor prognosis.2025Scientific reports免费全文
  11. Unraveling the Causal Links Between Immune Traits and Hepatocellular Carcinoma: Insights From a Bi-Directional Mendelian Randomization Study.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  12. G-LERP/miR-374i-b Attenuates IRI and Suppresses Hepatocellular Carcinoma Progression.2025Transplantation
  13. Microchip Based Isolation and Drug Delivery of Patient-Derived Extracellular Vesicles Against Their Homologous Tumor.2024Advanced healthcare materials
  14. Is DEB-TACE as locoregional therapy before liver transplantation for hepatocellular carcinoma effective?2024BMC gastroenterology免费全文
  15. Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells.2024Cellular & molecular immunology免费全文
  16. Heterogeneity of hepatocellular carcinoma that responds differently to combination therapy with TACE and Sorafenib as determined by digital spatial gene expression profiling.2024Genes & genomics
  17. Ferroptosis-inducing nanomedicine and targeted short peptide for synergistic treatment of hepatocellular carcinoma.2024Journal of nanobiotechnology免费全文
  18. Ferroptosis: a new promising target for hepatocellular carcinoma therapy.2024Molecular and cellular biochemistry
  19. mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.2024Molecular biomedicine免费全文
  20. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.2024The British journal of radiology免费全文
  21. Preoperative Nomogram Incorporating Clinical Factors, Serological Markers and LI-RADS MRI Features to Predict Early Recurrence of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.2023Academic radiology
  22. SSNA1 Promotes Hepatocellular Carcinoma Metastasis Via STAT3/EMT Induction.2023Anticancer research
  23. Scribble promotes fibrosis-dependent mechanisms of hepatocarcinogenesis by p53/PUMA-mediated glycolysis.2023Biochimica et biophysica acta. Molecular basis of disease
  24. Protein induced by vitamin K absence or antagonist II: Experience to date and future directions.2023Biochimica et biophysica acta. Reviews on cancer
  25. Vertically-Ordered Mesoporous Silica Film Based Electrochemical Aptasensor for Highly Sensitive Detection of Alpha-Fetoprotein in Human Serum.2023Biosensors免费全文
  26. BMI1-induced CD127+KLRG1+ memory T cells enhance the efficacy of liver cancer immunotherapy.2023Cancer letters
  27. Systemic analysis identifying PVT1/DUSP13 axis for microvascular invasion in hepatocellular carcinoma.2023Cancer medicine免费全文
  28. ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1.2023Cell communication and signaling : CCS免费全文
  29. A mixed blessing for liver transplantation patients - Rapamycin.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  30. Prognostic implication of early posttransplant hypercholesterolemia in liver transplantation for patients with hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  31. SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment.2023Hepatology (Baltimore, Md.)
  32. Current Status and Prospect of Delivery Vehicle Based on Mesenchymal Stem Cell-Derived Exosomes in Liver Diseases.2023International journal of nanomedicine免费全文
  33. Serum Exosome-Derived piRNAs Could Be Promising Biomarkers for HCC Diagnosis.2023International journal of nanomedicine免费全文
  34. Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  35. The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients.2023World journal of surgical oncology免费全文
  36. Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression.2022Acta pharmaceutica (Zagreb, Croatia)
  37. E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation.2022American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  38. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.2022BMC cancer免费全文
  39. Identification and Verification of a Novel MAGI2-AS3/miRNA-374-5p/FOXO1 Network Associated with HBV-Related HCC.2022Cells免费全文
  40. Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition).2022Chinese medical journal免费全文
  41. RNA binding protein-based risk score model for prognosis prediction of patients with hepatocellular carcinoma.2022Chinese medical journal免费全文
  42. Long-term outcomes of deceased donor liver transplantation in hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  43. Reply to 'How to select eligible hepatocellular carcinoma patients with portal vein tumor thrombus for deceased donor liver transplantation?'.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  44. One Shoot, Two Birds: Alleviating Inflammation Caused by Ischemia/Reperfusion Injury to Reduce the Recurrence of Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  45. Methylation site APC112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence.2022Future oncology (London, England)
  46. Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  47. Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study.2022Hepatology international免费全文
  48. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?2022International journal of biological sciences免费全文
  49. DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD.2022Journal of biomedical science免费全文
  50. Tumor-suppressive role of microfibrillar associated protein 4 and its clinical significance as prognostic factor and diagnostic biomarker in hepatocellular carcinoma.2022Journal of cancer research and therapeutics
  51. Comment on "Predictors of changes in preoperative tumor stage between dynamic computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging for hepatocellular carcinoma".2022Journal of the Formosan Medical Association = Taiwan yi zhi
  52. Association of RASSF1A Ala133Ser polymorphism with cancer risk: a updated meta-analysis involving 7362 subjects.2022Nucleosides, nucleotides & nucleic acids
  53. Multi-omics profiling reveals Chitinase-3-like protein 1 as a key mediator in the crosstalk between sarcopenia and liver cancer.2022Redox biology免费全文
  54. CLIC1 Drives Angiogenesis in Hepatocellular Carcinoma by Modulating VEGFA.2022Technology in cancer research & treatment免费全文
  55. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.2021Academic radiology
  56. Interleukin-2 inducible T-cell kinase: a potential prognostic biomarker and tumor microenvironment remodeling indicator for hepatocellular carcinoma.2021Aging免费全文
  57. Effects of terlipressin and somatostatin on liver function after major hepatectomy for hepatocellular carcinoma.2021Asian journal of surgery
  58. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).2021Biological chemistry
  59. The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib.2021Cell death & disease免费全文
  60. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.2021Clinical radiology
  61. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  62. Risk factors associated with suicide among hepatocellular carcinoma patients: A surveillance, epidemiology, and end results analysis.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology免费全文
  63. Key factors and potential drug combinations of nonalcoholic steatohepatitis: Bioinformatic analysis and experimental validation-based study.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  64. Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  65. LncRNA MEG8 plays an oncogenic role in hepatocellular carcinoma progression through miR-367-3p/14-3-3ζ/TGFβR1 axis.2021Neoplasma
  66. Combination therapy for HCC: from CRISPR screening to the design of clinical therapies.2021Signal transduction and targeted therapy免费全文
  67. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation.2021Transplantation reviews (Orlando, Fla.)
中文论文(未计入)2
  1. [Novel research horizon for liver transplantation management model in hepatocellular carcinoma based on the tumor-donor liver-recipient].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. Deep learning-based radiomics allows for a more accurate assessment of sarcopenia as a prognostic factor in hepatocellular carcinoma.2024Journal of Zhejiang University. Science. B免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma已完成NCT05907772研究中心2022-08 启动
  2. Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma已完成NCT05643833研究中心2021-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.1%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 0020222023: 2220232024: 2220242025: 332025

杭州有 9 家医院列在胃癌下全国有 211 家医院列在胃癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。

这些数字背后的记录
研究主题腹膜转移与晚期手术化疗与综合治疗
论文中的科室普外/肝胆胰外科消化/肝病科肿瘤内科病理/检验科
牵头的论文11
  1. Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.2025Annals of medicine免费全文
  2. Immunotherapy Combined with Chemotherapy in the First-Line Treatment of Advanced Gastric Cancer: Systematic Review and Bayesian Network Meta-Analysis Based on Specific PD-L1 CPS.2025Current oncology (Toronto, Ont.)免费全文
  3. The mir-371a-373 cluster: A crucial miRNA cluster promotes the malignancy of gastric cancer.2025Neoplasma
  4. The relationship between innate/adaptive immunity and gastrointestinal cancer : a multi-omics Mendelian randomization study.2024BMC gastroenterology免费全文
  5. Comprehensive analysis of the expression, prognostic, and immune infiltration for COL4s in stomach adenocarcinoma.2024BMC medical genomics免费全文
  6. Vernodalin Suppresses Tumor Proliferation and Increases Apoptosis of Gastric Cancer Cells Through Attenuation of FAK/PI3K/AKT/mTOR and MAPKs Signaling Pathways.2023Current pharmaceutical biotechnology
  7. The putative role of ferroptosis in gastric cancer: a review.2023European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)免费全文
  8. Efficiency of complete omentectomy in patients with resectable gastric cancer: a meta‑analysis and systematic review.2021BMC gastroenterology免费全文
  9. A population-based analysis of malignant gastric tumor in children.2021Journal of pediatric surgery
  10. Double Gastroscopy Resection Is a New Attempt to Treat Gastric Submucosal Tumors: A Case Report.2021The American journal of gastroenterology
  11. Exosomal NNMT from peritoneum lavage fluid promotes peritoneal metastasis in gastric cancer.2021The Kaohsiung journal of medical sciences免费全文
中文论文(未计入)1
  1. [Clinicopathological analysis of amphicrine carcinoma of the stomach].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. Treatment of Advance Gastric Cancer With Disulfiram状态不明NCT05667415研究中心不分期2023-06 启动
  2. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)已终止NCT04933227研究中心II期2021-08 启动
  3. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  4. Incidence of Pancreatic Fistula After Radical Gastrectomy状态不明NCT03391687研究中心2017-12 启动
  5. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  6. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  7. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 51 篇,占 0.2%。

牵头论文
51
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 7720222023: 9920232024: 141420242025: 12122025

杭州有 11 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
    分期
    未注明
    开始
    2025-04
    发布
    登记号
    NCT06862869

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、兰州、北京、南京、南昌、南通、台州、合肥、哈尔滨、大连、太原、广州、成都、无锡、杭州、武汉、江门、济南、深圳、湛江、石家庄、福州、西安、遵义、重庆、银川、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科肿瘤内科普外/肝胆胰外科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文51
  1. Rapid and Noninvasive Early Detection of Lung Cancer by Integration of Machine Learning and Salivary Metabolic Fingerprints Using MS LOC Platform: A Large-Scale Multicenter Study.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Identification and functional characterization of genes associated with lipopolysaccharide in lung adenocarcinoma.2025BMC cancer免费全文
  3. Blood-brain barrier alterations as an initiator of brain metastasis from lung cancer: a new take on an old story.2025Cancer gene therapy
  4. Assessing the carcinogenic potential and molecular mechanisms of arecoline in human lungs: from in silico methods to in vitro validation.2025Ecotoxicology and environmental safety
  5. Toripalimab plus chemotherapy as first-line treatment in extensive-stage small cell lung cancer: a health economic evaluation in China.2025Frontiers in public health免费全文
  6. Investigating the role of IDO1 in tumors: correlating IDO1 expression with clinical pathological features and prognosis in lung adenocarcinoma patients.2025PeerJ免费全文
  7. Investigating the correlation between IDO1/PD-L1 expression or co-expression and EGFR/KRAS gene mutations in advanced NSCLC.2025Scientific reports免费全文
  8. Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis.2025Scientific reports免费全文
  9. TtAgo-coupled-multiplex-digtal-RPA-CRISPR/Cas12a (TCMDC) for EGFR mutations detection.2025Talanta
  10. The study of transitional care on the psychological state of patients with advanced lung cancer chemotherapy.2025Technology and health care : official journal of the European Society for Engineering and Medicine
  11. Hepatic metastasis of pulmonary large cell neuroendocrine carcinoma: A case report and literature review.2025The Journal of international medical research免费全文
  12. Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer.2025eLife免费全文
  13. SEPT9: From pan-cancer to lung squamous cell carcinoma.2024BMC cancer免费全文
  14. Suppression of PERK/eIF2α/CHOP pathway enhances oridonin-induced apoptosis by inhibiting autophagy in Small-Cell lung cancer cells.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  15. Comprehensive utilization of in silico approach and in vitro experiment to unveil the molecular mechanisms of mono (2-ethylhexyl) phthalate-induced lung adenocarcinoma.2024Bioorganic chemistry
  16. Advances in Research on the Anticancer Properties and Mechanisms of Metformin in Lung Cancer.2024British journal of hospital medicine (London, England : 2005)
  17. Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  18. ITGB4 is a prognostic biomarker and correlated with lung adenocarcinoma brain metastasis.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  19. Functional Characterization of Reduced Folate Carrier and Protein-Coupled Folate Transporter for Antifolates Accumulation in Non-Small Cell Lung Cancer Cells.2024Drug metabolism and disposition: the biological fate of chemicals
  20. A Radiological-Radiomics model for differentiation between minimally invasive adenocarcinoma and invasive adenocarcinoma less than or equal to 3 cm: A two-center retrospective study.2024European journal of radiology
  21. Long-term survival of stage Ib lung adenocarcinoma with postoperative brain oligometastasis: a case report and literature review.2024Folia neuropathologica
  22. Detection of serum SNHG22 and its correlation with prognosis of non-small cell lung cancer.2024Journal of cardiothoracic surgery免费全文
  23. Taxus chinensis var. mairei (Lemée et Lévl) Cheng et L.K. Fu overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer via suppression of ERK1/2-related cholesterol biosynthesis.2024Journal of ethnopharmacology
  24. Potential of Targeting TDO2 as the Lung Adenocarcinoma Treatment.2024Journal of proteome research
  25. Oleandrin enhances radiotherapy sensitivity in lung cancer by inhibiting the ATM/ATR-mediated DNA damage response.2024Phytotherapy research : PTR
  26. SPTBN2 suppresses ferroptosis in NSCLC cells by facilitating SLC7A11 membrane trafficking and localization.2024Redox biology免费全文
  27. Scribble promotes fibrosis-dependent mechanisms of hepatocarcinogenesis by p53/PUMA-mediated glycolysis.2023Biochimica et biophysica acta. Molecular basis of disease
  28. Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation.2023Chemico-biological interactions
  29. CISD2 promotes lung squamous carcinoma cell migration and invasion via the TGF-β1-induced Smad2/3 signaling pathway.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  30. MFN2 deficiency affects calcium homeostasis in lung adenocarcinoma cells via downregulation of UCP4.2023FEBS open bio免费全文
  31. The second-generation tyrosine kinase inhibitor afatinib inhibits IL-1β secretion via blocking assembly of NLRP3 inflammasome independent of epidermal growth factor receptor signaling in macrophage.2023Molecular immunology
  32. A novel risk signature for predicting brain metastasis in patients with lung adenocarcinoma.2023Neuro-oncology免费全文
  33. Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.2023Thoracic cancer免费全文
  34. Characterization and mechanisms of radioresistant lung squamous cell carcinoma cell lines.2023Thoracic cancer免费全文
  35. Lung cancer patient with Tropheryma whipplei and Nocardia co-infection.2023Ultrastructural pathology
  36. Lung cancer metastasis-related protein 1 promotes the transferring from advanced metastatic prostate cancer to castration-resistant prostate cancer by activating the glucocorticoid receptor α signal pathway.2022Bioengineered免费全文
  37. SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer.2022Cancer letters
  38. Hope and Worry: An Interpretative Phenomenological Analysis of Psychological Experiences Associated With Targeted Drug Therapy Among Patients With Advanced Non-Small-Cell Lung Cancer.2022Cancer nursing
  39. TNFα antagonist in combination with PD-1 blocker to prevent or retard malignant transformation of B[a]P-induced chronic lung inflammation.2022Carcinogenesis
  40. Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.2022International journal of oncology免费全文
  41. Pulsatilla saponin E suppresses viability, migration, invasion and promotes apoptosis of NSCLC cells through negatively regulating Akt/FASN pathway via inhibition of flotillin-2 in lipid raft.2022Journal of receptor and signal transduction research
  42. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer.2022Tissue & cell
  43. Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.2021Acta pharmacologica Sinica免费全文
  44. GTSE1 Facilitates the Malignant Phenotype of Lung Cancer Cells via Activating AKT/mTOR Signaling.2021Analytical cellular pathology (Amsterdam)免费全文
  45. Effect of continuous nursing based on the Omaha System on cancer-related fatigue in patients with lung cancer undergoing chemotherapy: a randomized controlled trial.2021Annals of palliative medicineRCT
  46. LASP1 Induces Epithelial-Mesenchymal Transition in Lung Cancer through the TGF-β1/Smad/Snail Pathway.2021Canadian respiratory journal免费全文
  47. Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients.2021Frontiers in cellular and infection microbiology免费全文
  48. Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38.2021Investigational new drugs
  49. Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer.2021Journal of clinical laboratory analysis免费全文
  50. Sulforaphane overcomes T790M-mediated gefitinib resistance in vitro through epithelial-mesenchymal transition.2021Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  51. hsa_circ_0058357 acts as a ceRNA to promote non‑small cell lung cancer progression via the hsa‑miR‑24‑3p/AVL9 axis.2021Molecular medicine reports免费全文
中文论文(未计入)4
  1. [Intestinal Flora Dysregulation and Lung Cancer: 
Mechanism Analysis and Clinical Application].2025Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  2. [Establishment of Human Lung Adenocarcinoma Radioresistant Cell Lines
and the Mechanism of Radioresistance].2023Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  3. [Research Progress in CircRNA and Radiotherapy Resistance of Non-small Cell Lung Cancer].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  4. [Analysis of gut microbiome in patients with lung adenocarcinoma and lung squamous cell carcinoma].2021Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
  1. Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy正在招募NCT06862869研究中心2025-04 启动
  2. A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy已终止NCT06267001研究中心III期2024-03 启动
  3. Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer状态不明NCT04749407研究中心2021-02 启动
  4. A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)状态不明NCT04325763研究中心III期2020-05 启动
  5. Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)已完成NCT03829332研究中心III期2019-03 启动
  6. M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)已终止NCT03840902研究中心II期2019-04 启动
  7. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer状态不明NCT04641754研究中心II期2019-03 启动
  8. Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study已完成NCT04676412研究中心III期2019-10 启动
  9. A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients状态不明NCT03407300研究中心II期2018-02 启动
  10. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer已完成NCT03594747研究中心III期2018-07 启动
  11. A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer已完成NCT03663205研究中心III期2018-07 启动
  12. Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC状态不明NCT03300115研究中心II期2017-05 启动
  13. A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)状态不明NCT02714608研究中心II期2016-05 启动
  14. Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy状态不明NCT02787447研究中心II期2016-05 启动
  15. A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy已完成NCT02813785研究中心III期2016-07 启动
  16. A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer状态不明NCT02787473研究中心II期2016-10 启动
  17. A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)已完成NCT02657434研究中心III期2016-04 启动
  18. EGFR Mutations on ctDNA in Patients With Advanced NSCLC已完成NCT02623257研究中心2016-01 启动
  19. ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC状态不明NCT02946216研究中心2016-11 启动
  20. T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure已完成NCT02418234研究中心2015-03 启动
  21. Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer状态不明NCT02348450研究中心IV期2015-02 启动
  22. Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer状态不明NCT02215356研究中心II期2014-08 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 23 篇,占 0.4%。

牵头论文
23
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 6620222023: 4420232024: 5520242025: 552025

杭州有 9 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Canagliflozin With Gemcitabine in Pancreatic Carcinoma
    分期
    不分期
    开始
    2023-10
    发布
    登记号
    NCT05903703

    年龄 18 岁 至 未注明(登记的条件)

    牵头:杭州市第一人民医院杭州

  2. 正在招募
    Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer
    分期
    II期
    开始
    2025-05
    发布
    登记号
    NCT07006077

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科普外/肝胆胰外科肿瘤内科临床试验/研究机构

这些论文过半是实验室或动物研究。

牵头的论文23
  1. Complex interplay between type 2 diabetes mellitus and pancreatic cancer: insights from observational and mendelian randomization analyses.2025BMC cancer免费全文
  2. Demystifying metabolic‒immune crosstalk: how amino acid metabolic reprogramming shapes the malignant phenotype and macrophage polarization of biliary and pancreatic tumors.2025International journal of biological sciences免费全文
  3. Targeting RhoA expression with formononetin and salvianolic acid B to mitigate pancreatic cancer-associated endothelial cells changes.2025Journal of ethnopharmacology
  4. Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated degradation.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  5. Diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration-based cytology for distinguishing malignant and benign pancreatic cystic lesions: A systematic review and meta-analysis.2025PloS one免费全文
  6. The role of vascular resection and reconstruction in pancreaticoduodenectomy.2024Asian journal of surgery
  7. The characteristic "alveolus nest sign" in solid pseudopapillary neoplasm of the pancreas.2024Endoscopy免费全文
  8. Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and trigger endoplasmic reticulum stress.2024International immunopharmacology
  9. A pancreaticogastric fistula related to intraductal papillary mucinous neoplasm of the pancreas developed during follow-up: A case report and literature review.2024Journal of digestive diseases
  10. Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma.2024Oncoimmunology免费全文
  11. Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis.2023Biochemical pharmacology
  12. KNTC1 as a putative tumor oncogene in pancreatic cancer.2023Journal of cancer research and clinical oncology免费全文
  13. m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway.2023Journal of experimental & clinical cancer research : CR免费全文
  14. PDZ-binding kinase aggravates pancreatic neuroendocrine neoplasm progression by activating the AKT/mTOR pathway.2023Molecular carcinogenesis
  15. The net parenchymal thickness predicts pancreatic fistula after pancreaticoduodenectomy: a retrospective cohort study of objective data.2022ANZ journal of surgery
  16. CDC25C is a prognostic biomarker and correlated with mitochondrial homeostasis in pancreatic adenocarcinoma.2022Bioengineered免费全文
  17. Selective radical resection for unresectable pancreatic cancer.2022Cirugia y cirujanos
  18. CD44V3, an Alternatively Spliced Form of CD44, Promotes Pancreatic Cancer Progression.2022International journal of molecular sciences免费全文
  19. Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway.2022Journal of cellular and molecular medicine免费全文
  20. Immunological role and prognostic value of SPARCL1 in pan-cancer analysis.2022Pathology oncology research : POR免费全文
  21. The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma.2021Cell death & disease免费全文
  22. Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.2021Frontiers in immunology免费全文
  23. EIF3B promotes cancer progression in pancreatic cancer.2021Scandinavian journal of gastroenterology
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Canagliflozin With Gemcitabine in Pancreatic Carcinoma即将招募NCT05903703牵头方(推断)不分期2023-10 启动
  2. Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer正在招募NCT07006077研究中心II期2025-05 启动
  3. EUS-RFA for Unresectable Pancreatic Cancer已完成NCT04310111研究中心不分期2020-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 21 篇,占 0.1%。

牵头论文
21
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 2220222023: 2220232024: 9920242025: 552025

杭州有 9 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
    分期
    不分期
    开始
    2023-07
    发布
    登记号
    NCT07920094

    年龄 18 岁 至 70 岁;仅女性(登记的条件)

    牵头:浙江大学医学院附属邵逸夫医院;另有 10 家列出的医院为研究中心台州、宁波、杭州、温州、金华

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科病理/检验科肿瘤内科
牵头的论文21
  1. Effects of Continuous Perioperative Esketamine Infusion on Postoperative Depression in Breast Cancer Patients: A Randomized Controlled Double-Blind Trial.2025Drug design, development and therapyRCT免费全文
  2. Predicting Pathological Characteristics of HER2-Positive Breast Cancer from Ultrasound Images: a Deep Ensemble Approach.2025Journal of imaging informatics in medicine免费全文
  3. Pan-cancer analysis reveals BAF complexes as immune-related biomarkers and validation in triple-negative breast cancer.2025Life sciences
  4. AI in breast imaging: A systematic review of reader studies evaluating design, performance, and clinical impact.2025Medical physics
  5. Using artificial intelligence system for assisting the classification of breast ultrasound glandular tissue components in dense breast tissue.2025Scientific reports免费全文
  6. Patient-Reported Outcomes and Complication Profiles of Implant-Based Breast Reconstruction in Patients With Postmastectomy Radiation Therapy.2024Annals of plastic surgery
  7. Nomogram based on multimodal ultrasound features for evaluating breast nonmass lesions: a single center study.2024BMC medical imaging免费全文
  8. Detection and diagnosis of automated breast ultrasound in patients with BI-RADS category 4 microcalcifications: a retrospective study.2024BMC medical imaging免费全文
  9. The mechanism and therapeutic potential of lncRNA MIR497HG/miR-16-5p axis in breast cancer.2024BMC women's health免费全文
  10. Encapsulated Papillary Carcinoma of the Breast: A Review of Clinicopathologic Characteristics, Molecular Mechanisms, and Patient Management.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  11. ER-positive and BRCA2-mutated breast cancer: a literature review.2024European journal of medical research免费全文
  12. Novel immunotherapies for breast cancer: Focus on 2023 findings.2024International immunopharmacology
  13. Functions and mechanisms of RNA m6A regulators in breast cancer (Review).2024International journal of oncology免费全文
  14. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.2024Scientific reports免费全文
  15. Value of multimodal imaging in the diagnosis of breast sclerosing adenosis associated with malignant lesions.2023Journal of clinical ultrasound : JCU
  16. Accelerated Perioperative Rehabilitation for Breast Cancer Patients Undergoing Radical Mastectomy: A Systematic Review.2023Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses
  17. Nodular fasciitis of the breast: the report of three cases.2022BMC women's health免费全文
  18. β-elemene induced apoptosis and senescence of triple-negative breast cancer cells through IGF1/IGF1R pathway.2022Tissue & cell
  19. Value of quantitative sound touch elastography of tissues around breast lesions in the evaluation of malignancy.2021Clinical radiology
  20. Astragaloside IV inhibits cell proliferation and metastasis of breast cancer via promoting the long noncoding RNA TRHDE-AS1.2021Journal of natural medicines
  21. All-Trans Retinoic Acid and Doxorubicin Delivery by Folic Acid Modified Polymeric Micelles for the Modulation of Pin1-Mediated DOX-Induced Breast Cancer Stemness and Metastasis.2021Molecular pharmaceutics
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery正在招募NCT07920094研究中心不分期2023-07 启动
  2. Fertility Decision and Outcomes in Young Women With Breast Cancer进行中,不再招募NCT07804745研究中心2025-10 启动
  3. A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer进行中,不再招募NCT06561607研究中心III期2024-10 启动
  4. Exploring a Breast Cancer Early Screening Model Based on cfDNA已完成NCT06016790研究中心2023-04 启动
  5. To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer进行中,不再招募NCT05365178研究中心III期2022-07 启动
  6. Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA)状态不明NCT03589924研究中心不分期2018-06 启动
  7. Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer已完成NCT03084939研究中心III期2017-04 启动
  8. A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer已完成NCT02896855研究中心III期2016-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胶质瘤

Glioma

2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.1%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 3320242025: 222025

杭州有 9 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。

这些数字背后的记录
论文中的科室神经外科临床试验/研究机构儿科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

杭州有 5 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

杭州有 20 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 12 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025

杭州有 9 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    发布
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层双抗与抗体药物复发与耐药

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.2%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 2220242025: 332025

杭州有 8 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
    分期
    II期
    开始
    2025-03
    发布
    登记号
    NCT07022223

    年龄 18 岁 至 未注明(登记的条件)

    牵头:浙江大学医学院附属第二医院;另有 2 家列出的医院为研究中心杭州

  2. 正在招募
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    分期
    II/III期
    开始
    2024-05
    发布
    登记号
    NCT06378138

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、合肥、大连、天津、太原、宜昌、广州、成都、杭州、武汉、沈阳、洛阳、济南、淮安、石家庄、福州、蚌埠、西安、遵义、郑州、重庆、长春、长沙

  3. 正在招募
    Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
    分期
    III期
    开始
    2024-08
    发布
    登记号
    NCT06520163

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:宁波大学附属人民医院;另有 3 家列出的医院为研究中心宁波、杭州、温州

  4. 正在招募
    Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06521255

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、天津、广州、成都、杭州、武汉、济南、温州、苏州、郑州、重庆、长春、长沙

  5. 正在招募
    A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
    分期
    I期
    开始
    2023-10
    发布
    登记号
    NCT05892718

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科
牵头的论文7
  1. Bi-targeting of thioredoxin 1 and telomerase by thiotert promotes cell death of myelodysplastic syndromes and lymphoma.2025Biology direct免费全文
  2. Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma.2025Blood advances免费全文
  3. Overcoming missed diagnoses of primary central nervous system Lymphoma-The key role of cerebrospinal fluid cytology: a case report.2025Diagnostic pathology免费全文
  4. SNCA is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients.2024Apoptosis : an international journal on programmed cell death免费全文
  5. DLD is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients.2024Apoptosis : an international journal on programmed cell death免费全文
  6. Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin's Lymphoma.2022Acta dermato-venereologica免费全文
  7. Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report.2021Immunotherapy
中文论文(未计入)1
  1. [Thromboelastography Combined with Blood D-Dimer in the Prediction of Lower Extremity Venous Thrombosis in Patients with Diffuse Large B-Cell Lymphoma].2025Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma正在招募NCT07022223研究中心II期2025-03 启动
  2. Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma正在招募NCT06520163研究中心III期2024-08 启动
  3. ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)正在招募NCT06378138研究中心II/III期2024-05 启动
  4. Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma正在招募NCT06521255研究中心III期2024-05 启动
  5. A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors正在招募NCT05892718研究中心I期2023-10 启动
  6. Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL状态不明NCT05186558研究中心II期2022-05 启动
  7. HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma已完成NCT05190068研究中心I期2022-01 启动
  8. An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma已完成NCT01340443研究中心2011-01 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.3%。

牵头论文
16
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 4420222023: 2220232024: 4420242025: 332025

杭州有 11 家医院列在冠心病下全国有 231 家医院列在冠心病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
    分期
    IV期
    开始
    2025-11
    发布
    登记号
    NCT07110415

    年龄 40 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、兰州、北京、南京、南宁、哈尔滨、大庆、大连、天津、宁波、广州、张家口、成都、杭州、汕头、沈阳、济南、深圳、湖州、烟台、珠海、石家庄、西安、贵阳、重庆、银川、长春、青岛

  2. 即将招募
    OPTIMized Diagnosis and Treatment System Based on AI and Multimodal Imaging Fusion for PCI (OPTIMAI-PCI)
    分期
    不分期
    开始
    2026-09
    发布
    登记号
    NCT07855614

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:浙江医院;另有 6 家列出的医院为研究中心杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文16
  1. Association between coronary heart disease and cardiometabolic index: a study from NHANES 1999-2018.2025BMC cardiovascular disorders免费全文
  2. Genetic mapping of serum metabolome to chronic diseases among Han Chinese.2025Cell genomics免费全文
  3. Comparison of Coronary Angiographic-Derived and Intracoronary Imaging-Based Fractional Flow Reserve in Assessing Coronary Artery Stenosis Severity: A Systematic Review and Network Meta-Analysis.2025Journal of evidence-based medicine免费全文
  4. Investigating the Correlation between Serum Amyloid A and Infarct-Related Artery Patency Prior to Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients.2024Angiology
  5. Quantitative Flow Ratio-Derived Index of Microcirculatory Resistance as a Novel Tool to Identify Microcirculatory Function in Patients with Ischemia and No Obstructive Coronary Artery Disease.2024Cardiology免费全文
  6. Predictive value of coronary artery computed tomography-derived fractional flow reserve for cardiovascular events in patients with coronary artery disease.2024Herz
  7. Association between personality traits and psychological distress among postmenopausal women with coronary heart disease: A cross-sectional survey and mediation analysis.2024Nursing & health sciences
  8. The Importance of Integrated Regulation Mechanism of Coronary Microvascular Function for Maintaining the Stability of Coronary Microcirculation: An Easily Overlooked Perspective.2023Advances in therapy
  9. Alterations in gut microbiota and host transcriptome of patients with coronary artery disease.2023BMC microbiology免费全文
  10. Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease.2022BMC cardiovascular disorders免费全文
  11. The correlation between lipoprotein(a) elevations and the risk of recurrent cardiovascular events in CAD patients with different LDL-C levels.2022BMC cardiovascular disorders免费全文
  12. A comment and suggestion on angiography-derived FFR: NiFFR.2022Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  13. An attempt to better show some results such as the comparison of mortality and major adverse cardiovascular events between the abnormal and normal coronary flow reserve cohorts.2022European heart journal
  14. Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.2021Journal of the American Heart Association免费全文
  15. RNA modifications in cardiovascular diseases, the potential therapeutic targets.2021Life sciences
  16. Integration of summary data from GWAS and eQTL studies identified novel risk genes for coronary artery disease.2021Medicine免费全文
中文论文(未计入)1
  1. [Correlation of mitochondrial tRNA variants with coronary heart disease in a Chinese pedigree].2023Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. OPTIMized Diagnosis and Treatment System Based on AI and Multimodal Imaging Fusion for PCI (OPTIMAI-PCI)即将招募NCT07855614研究中心不分期2026-09 启动
  2. Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction正在招募NCT07110415研究中心IV期2025-11 启动
  3. FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease进行中,不再招募NCT06218485研究中心不分期2024-03 启动
  4. Wedge NC - Scoring Balloon Dilatation Catheter已完成NCT06214247研究中心不分期2021-08 启动
  5. Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease进行中,不再招募NCT04397211研究中心不分期2020-05 启动
  6. Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease已完成NCT04078568研究中心III期2020-01 启动
  7. Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease已完成NCT01735305研究中心2012-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

杭州有 9 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

杭州有 10 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    发布
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙

  2. 正在招募
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    分期
    II期
    开始
    2025-11
    发布
    登记号
    NCT07121413

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、南京、南昌、呼和浩特、天津、广州、徐州、成都、杭州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

杭州有 10 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease
    分期
    不分期
    开始
    2025-03
    发布
    登记号
    NCT06765499

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 7 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

杭州有 7 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

杭州有 7 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 10 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression进行中,不再招募NCT05797610研究中心III期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

杭州有 7 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
牵头的论文1
  1. Risk factors for recurrent primary biliary cirrhosis after liver transplantation: A systematic review and meta-analysis.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年没有牵头Leber 遗传性视神经病变的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

杭州有 5 家医院列在Leber 遗传性视神经病变下全国有 30 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

杭州市第一人民医院

Hangzhou First People's Hospital

杭州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Affiliated Hangzhou First People's Hospital; Changzhou First People's Hospital; Affiliated Hangzhou First Hospital; Affiliated Hangzhou First People Hospital; Changzhou & Changzhou First People's Hospital; Hangzhou first people's Hospital; Hangzhou First People Hospital; Changzhou First Hospital

提出更正下载数据